AP NEWS
Click to copy
Press release content from ACCESSWIRE. The AP news staff was not involved in its creation.
Click to copy
PRESS RELEASE: Paid content from ACCESSWIRE
Press release content from ACCESSWIRE. The AP news staff was not involved in its creation.

Discovery Investment Research Provides Update on Medexus Pharma

September 10, 2019

DIR Announces Availability of Research Update

PHOENIX, AZ / ACCESSWIRE / September 10, 2019 / Discovery Investment Research (DIR), an equity research firm specializing in micro and small-cap stocks, announces the availability of a research update on Medexus Pharma (PDDPF) (MDP). The update on Medexus Pharma, a specialty pharmaceutical company with operations in Canada and the United States, can be obtained by visiting DIR’s website ( www.discoveryinvresearch.com ). The following key attributes serve as the basis for DIR’s current recommendation:

About Pediapharm

Pediapharm is a specialty pharmaceutical company with operations in both Canada and the United States. The company markets several products aimed at niche markets for both children and adults, including pharmaceuticals for Rheumatoid Arthritis and other auto-immune disorders.

CONTACTS:

Roland Boivin Chief Financial Officer Pediapharm Inc. Tel.: 514-762-2626 ext. 202 E-mail: Frank Candido Direct Financial Strategies and Communication Inc. Tel. 514-969-5530 E-mail:

SOURCE: Discovery Investment Research

View source version on accesswire.com:

All contents © copyright 2019 The Associated Press. All rights reserved.